信大医学部研究紹介2021(英語版)_プレス品質
28/48

26Exploring perioperative and long-term problems associated with liver transplantation Promoting pancreatic islet cell transplantationTransplant and Pediatric SurgeryTransplant and Pediatric Surgery((Chief: Senior Assistant Prof. Atsuyoshi MitaChief: Senior Assistant Prof. Atsuyoshi Mita))Surgery(Gastroenterological)Summary of Activity・The first case of living donor liver transplantation in our institute was per-formed in 1990, and more than 300 cases have been experienced. We will continue to provide careful patient care to overcome life threatening problems, such as rejection, infection, and de novo cancer after transplantation. ・For clinical islet transplantation program, our institution is approved by Minister for HLW* to provide Class I Regenerative Medicine under the Act on the Safe-ty of Regenerative Medicine in 2015.・To solve perioperative and long-term problems associated with liver transplantation・Simulation training to improve islet isolation techniques ・To investigate how to protect pancreatic islets・Appling knowledge of our over 20 years of practice to improve the outcome after liver transplantation・To promote islet transplantation therapy in Japan along with other institutions・To become a transplant surgeon having a deep knowledge of immune system, cell protec-tion, and patient care.Research subjectOutlook for researchOutlook for students after graduationThe upper graph is Kaplan-Meier patient survival curve. The over all survival in a total of 39 cases for recent seven years was 95%. Islets for islet transplantationIslets (stained on red) isolated from a donor’s pancreas are transplanted into the liver through the portal vein.* Health, Labour and WelfareTo oer the most appropriate and advanced care for the patientsCardiovascular SurgeryCardiovascular Surgery((Prof. Tatsuichiro SetoProf. Tatsuichiro Seto))SurgerySummary of ActivityWe are conducting surgical treatment for cardiovascular diseases, peripheral vascular diseases including venous and lymphatic vessels, from heart disease to peripheral organs in the body as a whole. Particularly in multidisciplinary therapy for patients with severe systemic complications, elderly patients, patients with complex lesions, taking advantage of the university hospital, we offer medical treatment aiming for safer and more reliable surgery considering the patient’s long-term prognosis.・Research and development of cardiac regenerative therapy using iPS cell.・Research and development of surgery for thoracoabdominal aneurysm.・Research and development of novel site-selective ischemic disease therapeutic using recombinant bifidobacteria・Research and development of cardiac allograft rejection In medicine, it is said that today’s contraindications are tomorrow’s indications.Things that are forbidden today because something cannot be overcome may be permitted tomorrow thanks to just one breakthrough.We run practical training programs with specific goals that include understanding all charged cases and diseases, learning basic surgical procedures, and improving presentation tech-niques.Research subjectOutlook for researchOutlook for students after graduationState of cardiac surgeryCardiac regenerative therapy using iPS cell.“Modified from Shiba, et al. Nature 2016;  538: 388-391.”novel site-selective ischemic disease therapeutic using recombinant bidobac-teria

元のページ  ../index.html#28

このブックを見る